Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) announced Monday that Shaheen Wirk resigned from its board of directors on July 8. According to a statement from the company, Dr. Wirk’s decision to step down was not the result of any disagreement with Tvardi Therapeutics.
Dr. Wirk joined the board in March 2024 after previously serving as a special advisor to both the company and the board. The company expressed appreciation for Dr. Wirk’s contributions during his tenure.
This information is based on a press release statement included in a recent SEC filing.
In other recent news, Tvardi Therapeutics Inc has been the focus of several analyst firms, each initiating coverage with optimistic ratings. Raymond (NSE:RYMD) James has rated Tvardi with an Outperform rating and a $62.00 price target, highlighting the potential of their lead drug candidate, TTI-101, in treating idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC). Cantor Fitzgerald also initiated coverage with an Overweight rating and a $52.00 price target, emphasizing TTI-101’s ongoing proof-of-concept study for IPF, with results anticipated in the fourth quarter of 2025. Piper Sandler has given an Overweight rating with a $78.00 price target, noting Tvardi’s recent reverse merger with Cara Therapeutics and its financial runway extending into 2026. BTIG maintained a Buy rating with a $55.00 price target, highlighting the completion of enrollment for the Phase 2 IPF trial and the potential for TTI-101 to reverse disease progression. Oppenheimer set an Outperform rating with a $65.00 price target, projecting significant sales potential for TTI-101 by 2040 and noting promising interim data for both IPF and HCC treatments. These developments reflect a generally positive outlook from analysts on Tvardi’s financial and developmental trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.